Not Cleared Direct

DEN210038 - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Reagent Pack, VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Calibrator (FDA 510(k) Clearance)

May 2023
Decision
592d
Days
Class 2
Risk

DEN210038 is an FDA 510(k) submission for the VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Reagent Pack, VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Calibrator. This device is classified as a Sars-cov-2 Serology Test (Class II - Special Controls, product code QVP).

Submitted by Ortho-Clinical Diagnostics, Inc. (Rochester, US). The FDA issued a Not Cleared (DENG) decision on May 5, 2023.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.3983. A Sars-cov-2 Serology Test Is A Prescription In Vitro Diagnostic Device For The Detection Of Specific Binding Antibodies To Sars-cov-2 In Clinical Specimens. The Detection Of Sars-cov-2 Antibodies Is Intended To Aid In Identifying Individuals With An Adaptive Immune Response To Sars-cov-2. The Test Is Not Intended For The Diagnosis Of Acute Sars-cov-2 Infection, Nor Screening Blood, Plasma, Cells, Or Tissue Donors..

Submission Details

510(k) Number DEN210038 FDA.gov
FDA Decision Not Cleared Not Substantially Equivalent (DENG)
Date Received September 20, 2021
Decision Date May 05, 2023
Days to Decision 592 days
Submission Type Direct
Review Panel Microbiology (MI)
Summary

Device Classification

Product Code QVP — Sars-cov-2 Serology Test
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.3983
Definition A Sars-cov-2 Serology Test Is A Prescription In Vitro Diagnostic Device For The Detection Of Specific Binding Antibodies To Sars-cov-2 In Clinical Specimens. The Detection Of Sars-cov-2 Antibodies Is Intended To Aid In Identifying Individuals With An Adaptive Immune Response To Sars-cov-2. The Test Is Not Intended For The Diagnosis Of Acute Sars-cov-2 Infection, Nor Screening Blood, Plasma, Cells, Or Tissue Donors.